Alterola Biotech is a pre-revenue, early-stage pharmaceutical development company focused on cannabinoid and cannabinoid-like molecules with therapeutic applications. The company operates through three subsidiaries or licensed technologies: Phytotherapeutix, which develops novel molecules with CBD-like pharmacological activity intended as regulated pharmaceuticals for humans and animals; Ferven, which works on producing cannabinoids via fermentation using genetically modified organisms to achieve low-cost APIs and food-grade ingredients; and a nano-formulation drug delivery platform licensed exclusively from Nano4M, aimed at improving bioavailability and stability of drug candidates. Alterola has no approved products, no commercial customers, and has not completed any preclinical or clinical trials. Beyond pharmaceuticals, Alterola intends to pursue Novel Food approvals in Europe for cannabinoid food and dietary supplement ingredients, and to supply cannabinoid ingredients to cosmetics companies in permissible markets. Longer-term, the company is open to joint ventures, licensing deals, and acquisitions to broaden its portfolio. With a minimal team and no revenue, Alterola is entirely dependent on external financing, and its near-term focus is on building its IP portfolio and demonstrating scientific proof of concept before advancing candidates through formal regulatory pathways toward potential FDA or EMA approval.